Future growth expectations in sales/revenue/volumes?

The company expects around **20% topline (revenue) growth** in FY2024 compared to FY2023. Growth drivers include existing businesses, ARV segment revival, anti-diabetic segment, and Ibuprofen volumes. ARV business contribution is anticipated to be around **20%** in coming quarters, marking a recovery from previous low levels. Capacity utilization is targeted to improve to **75-80%** in FY2024, supporting volume growth. Ibuprofen commercial capacity is expanding from **300 MT to 700-900 MT per month** within six months, aiding volume increase. The company aims to consolidate current c

Future growth expectations in earnings/operating earnings/profits/EPS?

SMS Pharmaceuticals is targeting around 20% topline growth in FY2024 compared to FY2023. EBITDA margins are expected to improve towards 17%, with aims to achieve pre-COVID levels of around 20% margin over the next two years. ARV segment EBITDA margin is expected to be around 15%, with a revenue contribution targeted at approximately 20%. The company plans better margin realization through vertical integration, backward integration, and in-house production of key starting materials to optimize costs. Raw material prices have stabilized, which is expected to support margin expansion grad

Current/ Expected Orderbook/ Pending Orders?

The ARV (Antiretroviral) segment has recently added more customers, with orders now starting to flow in. Healthy orders of ARV products are expected for at least the next two to three quarters. The company expects a decent contribution from the ARV segment, targeting around 20% revenue contribution. The operating segment is tender-driven, but SMS Pharmaceuticals is only an API player; formulators bid for tenders. No specific values for the current order book or pending orders are disclosed in the transcript. Overall, the outlook suggests a growing and steady order inflow in key segments like A

Any current/future new fundraising through debt or equity?

No major capex or new fundraising planned for FY2024 as the company aims to consolidate cash flows and revenue. No current plans for Greenfield or Brownfield expansions, indicating limited immediate need for debt or equity raising. Regular maintenance capex only, suggesting stable capital expenditure without large funding requirements. Any major capex or fundraising may be considered from FY2025 onwards, depending on FY2024 performance. Overall focus is on optimizing existing operations and R&D for margin improvement rather than expansion requiring external funding.

Any current/future capex/capital investment/strategic investment?

No major capex planned for FY2024; focus is on consolidating cash flows and driving revenue growth first. Only regular, normal plant maintenance capex expected in FY2024, nothing extraordinary. No plans for Greenfield or Brownfield expansions currently; company prefers to consolidate operations before new projects. Potential capex may be considered in FY2025 depending on FY2024 performance. R&D investment is focused on cost optimization, backward integration (making intermediates and KSMs in-house), and exploring new therapeutic categories. Increasing capacity utilization (targeting

IN US

Sale is live|00:00:00left today

SMS Pharmaceuticals LtdQ1 FY23Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Ltd Q1 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹377P/E: 43.0Market Cap: ₹3.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Order

Yes

Capex

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→The company expects around **20% topline (revenue) growth** in FY2024 compared to FY2023.
→Growth drivers include existing businesses, ARV segment revival, anti-diabetic segment, and Ibuprofen volumes.
→ARV business contribution is anticipated to be around **20%** in coming quarters, marking a recovery from previous low levels.
→Capacity utilization is targeted to improve to **75-80%** in FY2024, supporting volume growth.
→Ibuprofen commercial capacity is expanding from **300 MT to 700-900 MT per month** within six months, aiding volume increase.
→The company aims to consolidate current capacities before future expansions, with no major capex planned in FY2024.
→Growth is expected to be supported by increased domestic and semi-regulated market presence, particularly for products like alfuzosin.

Margin guidance

Category 1

→SMS Pharmaceuticals is targeting around 20% topline growth in FY2024 compared to FY2023.
→EBITDA margins are expected to improve towards 17%, with aims to achieve pre-COVID levels of around 20% margin over the next two years.
→ARV segment EBITDA margin is expected to be around 15%, with a revenue contribution targeted at approximately 20%.
→The company plans better margin realization through vertical integration, backward integration, and in-house production of key starting materials to optimize costs.
→Raw material prices have stabilized, which is expected to support margin expansion gradually.
→Ibuprofen volumes are expected to grow substantially with capacity increasing from 300 MT to 700-900 MT per month over six months, supporting revenue growth.
→Focus on R&D and cost optimization is seen as a key driver to improve operating profitability going forward.

3 more insights locked — sign up free to unlock

Fundraise plans

→No major capex or new fundraising planned for FY2024 as the company aims to consolidate cash flows and revenue.
→No current plans for Greenfield or Brownfield expansions, indicating limited immediate need for debt or equity raising.
→Regular maintenance capex only, suggesting stable capital expenditure without large funding requirements.
→Any major capex or fundraising may be considered from FY2025 onwards, depending on FY2024 performance.
→Overall focus is on optimizing existing operations and R&D for margin improvement rather than expansion requiring external funding.

Order book

Yes

→The ARV (Antiretroviral) segment has recently added more customers, with orders now starting to flow in.
→Healthy orders of ARV products are expected for at least the next two to three quarters.
→The company expects a decent contribution from the ARV segment, targeting around 20% revenue contribution.
→The operating segment is tender-driven, but SMS Pharmaceuticals is only an API player; formulators bid for tenders.
→No specific values for the current order book or pending orders are disclosed in the transcript.
→Overall, the outlook suggests a growing and steady order inflow in key segments like ARV for FY2024.

Capex plans

→No major capex planned for FY2024; focus is on consolidating cash flows and driving revenue growth first.
→Only regular, normal plant maintenance capex expected in FY2024, nothing extraordinary.
→No plans for Greenfield or Brownfield expansions currently; company prefers to consolidate operations before new projects.
→Potential capex may be considered in FY2025 depending on FY2024 performance.
→R&D investment is focused on cost optimization, backward integration (making intermediates and KSMs in-house), and exploring new therapeutic categories.
→Increasing capacity utilization (targeting 75-80% for FY2024) before pursuing any capacity expansions.

How does SMS Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1SMS Pharmaceuticals Ltd

Rev 2Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like SMS Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio